Volume 4.40 | Oct 11

Mammary Cell News 4.40 October 11, 2012
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Mammary Cell News on Twitter
TOP STORY
Selective Inhibition of HER2-Positive Breast Cancer Cells by the HIV Protease Inhibitor Nelfinavir
Researchers conducted a pharmacological profiling of seven genotypically distinct breast cancer cell lines using a subset of inhibitors of breast cancer cells from a screen of the Johns Hopkins Drug Library. To identify molecular targets of nelfinavir, identified in the screen as a selective inhibitor of HER2-positive cells, they conducted a genome-wide screen of a haploinsufficiency yeast mutant collection. [J Natl Cancer Inst] Abstract | Press Release

Learn More: Column-Free Enrichment of Mouse Mammary Stem & Progenitor Cells
PUBLICATIONS (Ranked by impact factor of the journal)

LABORATORY RESEARCH

Synergy of Topical Toll-Like Receptor 7 Agonist with Radiation and Low Dose Cyclophosphamide in a Mouse Model of Cutaneous Breast Cancer
Researchers tested the hypothesis that topical Toll-Like Receptor (TLR) 7 agonist imiquimod promotes anti-tumor immunity and synergizes with other treatments in a model of skin-involving breast cancer. [Clin Cancer Res] Abstract

E3 Ubiquitin Ligase RNF126 Promotes Cancer Cell Proliferation by Targeting the Tumor Suppressor p21 for Ubiquitin-Mediated Degradation
To identify novel oncogenic E3 ubiquitin ligases as anti-cancer targets, scientists screened an E3 ubiquitin ligase siRNA library containing siRNA pools against 555 individual E3s using the SRB assay in the MDA-MB-231 breast cancer cell line and the PC3 prostate cancer cell line. RNF126 was identified and validated as a candidate from this screening. [Cancer Res] Abstract

Breast Tumor-Associated Osteoblast-Derived CXCL5 Increases Cancer Progression by ERK/MSK1/Elk-1/Snail Signaling Pathway
Researchers analyzed the soluble factors secreted by breast tumor-associated osteoblasts (TAOBs), which are responsible for promoting cancer progression. The addition of CXCL5 (chemokine (C-X-C motif) ligand 5), present in large amounts in TAOB-condition medium (TAOB-CM), mimicked the inductive effect of TAOB-CM on breast cancer epithelial-mesenchymal transition, migration and invasion. [Oncogene] Abstract

Downregulation of Stromal BRCA1 Drives Breast Cancer Tumor Growth via Upregulation of HIF-1a, Autophagy and Ketone Body Production
Researchers stably knocked-down BRCA1 expression in human hTERT-immortalized fibroblasts (shBRCA1) using an shRNA lentiviral approach. As expected, shBRCA1 fibroblasts displayed an elevated growth rate. [Cell Cycle] Abstract

Specific Inhibition of Notch1 Signaling Enhances the Antitumor Efficacy of Chemotherapy in Triple Negative Breast Cancer through Reduction of Cancer Stem Cells
Researchers generated Notch1 monoclonal antibodies that specifically bind to the negative regulatory region of human Notch1. Notch1 inhibition in triple negative breast cancer Sum149 and patient derived xenograft 144580 models led to significant TGI particularly in combination with docetaxel. [Cancer Lett] Abstract

Negative Regulation of NF-κB by the ING4 Tumor Suppressor in Breast Cancer
Investigators present evidence that the Inhibitor of Growth 4 (ING4) tumor suppressor negatively regulates Nuclear Factor kappa B (NF-κB) in breast cancer. They surveyed primary breast tumor samples for ING4 protein expression using tissue microarrays and a newly generated antibody. [PLoS One] Full Article

Zinc Inhibits Magnesium-Dependent Migration of Human Breast Cancer MDA-MB-231 Cells on Fibronectin
Researchers hypothesized that zinc, a divalent cation, can modulate breast cancer metastasis through interfering with divalent cation-dependent integrin-mediated cancer cell adhesion and migration. MDA-MB-231 cells were cultured in a zinc-depleted medium supplemented with 0 (control), 2.5, 5, 10, 25 and 50 µM of zinc to mimic severe zinc-deficiency, moderate zinc-deficiency, adequate zinc and three levels of zinc-supplementation: low-, moderate- and high-levels of zinc-supplementation, respectively. [J Nutr Biochem] Abstract

Decidua Mesenchymal Stem Cells Migrated toward Mammary Tumors In Vitro and In Vivo Affecting Tumor Growth and Tumor Development
Researchers aimed to investigate the migration capacity of decidua-derived mesenchymal stem cells (DMSCs) in vitro, and in vivo in a preclinical model of mammary tumors induced by N-nitroso-N-methylurea. Additionally, they assessed the safety of DMSC administration in vivo and their effect on tumor growth. [Cancer Gene Ther] Abstract

Programmed Cell-to-Cell Variability in Ras Activity Triggers Emergent Behaviors during Mammary Epithelial Morphogenesis
Variability in signaling pathway activation between neighboring epithelial cells can arise from local differences in the microenvironment, noisy gene expression, or acquired genetic changes. To investigate the consequences of this cell-to-cell variability in signaling pathway activation on coordinated multicellular processes such as morphogenesis, researchers used DNA-programmed assembly to construct three-dimensional MCF10A microtissues that are mosaic for low-level expression of activated H-Ras. [Cell Reports] Abstract

CLINICAL RESEARCH

Zoledronic Acid (Zoledronate) for Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole (ZO-FAST study): Final 60-Month Results
Postmenopausal women receiving adjuvant letrozole were randomly assigned to immediate zoledronic acid (zoledronate) 4 mg every six months for five years, or delayed zoledronate. The primary end point was the change in lumbar spine bone mineral density (BMD) at 12 months. Lumbar spine and total hip BMD at subsequent follow-up, disease-free survival, and overall survival were assessed as secondary end points. [Ann Oncol] Abstract

Brain-Only Metastatic Breast Cancer Is a Distinct Clinical Entity Characterized by Favorable Median Overall Survival Time and a High Rate of Long-Term Survivors
All breast cancer patients with brain metastases treated at the authors’ institution between 1990 and 2011 were identified. For each patient, full information on follow-up and administered therapies was mandatory for inclusion. Oestrogen receptor, progesterone receptor and Her2 status were determined according to standard protocols. Statistical analyses including computation of survival probabilities was performed. [Br J Cancer] Abstract

Don't Lose Sleep Over Mouse Mammary Tissue Dissociation (New Enzymes: Learn More)

REVIEWS
The RUNX Family in Breast Cancer: Relationships with Estrogen Signaling
The three RUNX family members are lineage specific master regulators, which also have important, context-dependent roles in carcinogenesis as either tumor suppressors or oncogenes. The authors reviewed evidence for such roles in breast cancer. [Oncogene] Abstract
INDUSTRY NEWS

The Nobel Prize in Physiology or Medicine 2012: Sir John B. Gurdon, Shinya Yamanaka
Nobel Assembly at Karolinska Institutet has decided to award The Nobel Prize in Physiology or Medicine 2012 jointly to John B. Gurdon and Shinya Yamanaka for the discovery that mature cells can be reprogrammed to become pluripotent. [Nobel Media AB] Press Release

George Washington Professor Awarded Grant to Study New Methods of Early Breast Cancer Detection
Sidney Fu received a two-year, $362,060 grant from the National Cancer Institute and hopes to develop a blood test to determine with greater precision whether a patient carries cells that will eventually turn into breast cancer. This test could save women all around the world from unnecessary trauma and stress from chemotherapy, radiation, and surgery. [George Washington School of Medicine and Health Sciences]
Press Release

When it Comes to Treating Breast Cancer, ‘Doing Less Does More’
The Seattle Cancer Care Alliance released a summary of “less-is-more” trends in four areas – drug therapy, radiation therapy, surgery and radiology – from the perspective of breast cancer specialists. [Seattle Cancer Care Alliance] Press Release

Acceleron and Collaborators Present Data on Potential Biomarkers for Metastatic Breast Cancer and Head and Neck Cancer at the “2012 Markers in Cancer” Conference
Acceleron Pharma, Inc. and its collaborators are presenting data at the 2012 Markers in Cancer Conference in Hollywood, Fla., that illustrate possible new biomarkers for use in metastatic breast cancer and in squamous cell carcinoma of the head and neck. The two poster presentations describe the potential role of activin A as an adverse biomarker for patients with metastatic breast cancer and of BMP9 as a biomarker for the identification and selection of patients with head and neck cancer. [Acceleron Pharma, Inc.] Press Release

POLICY NEWS

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS
NEW Frontiers in Cancer Science 2012
November 5-8, 2012
Singapore, Singapore

Visit
our events page to see a complete list of events in the mammary cell community.
JOB OPPORTUNITIES

Quality Control Operations Coordinator (STEMCELL Technologies, Inc.)

Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Research Technologist – Research and Development (STEMCELL Technologies, Inc.)

Scientific Communications & Publishing Coordinator (STEMCELL Technologies, Inc.)

Product Manager – Hematopoietic (STEMCELL Technologies, Inc.)


Assistant Professor – Breast Cancer Research (Johns Hopkins University)

Postdoctoral Position – Stem Cell/Cancer/Developmental Biology (Tufts University School of Medicine)

Postdoctoral Fellow – Gene Regulation in Breast Cancer/Stem Cell Biology (University of Cincinnati)

Associate Attending Breast Pathologist (Memorial Sloan-Kettering Cancer Center)

Postdoctoral Fellow – Breast Cancer Research (Mayo Clinic)


Recruit Top Talent
: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mammary Cell News: Archives | Events | Contact Us